Fig. 3From: Evaluating in vivo efficacy – toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cellsIn vivo safety profile of TEG001. (a) Schematic overview of the safety experiment in healthy donor-derived xenograft (H-DX) model. NSG mice were irradiated at day 0 and engrafted with healthy cord blood-derived CD34+ progenitor cells on day 1. Engraftment was followed-up in peripheral blood by flow cytometry and when > 500 huCD45+ cells/ml were present, mice received 2 injections of therapeutic TEG001 or TEG-LM1 mock in the presence of PAM (at week 6 and 8) and IL-2 (at week 6); (b-c) In vivo safety profile of TEG001 towards healthy human hematopoietic cells. Healthy human cells engrafted in NSG mice (b) with long-term persistence of TEGs in peripheral blood (c). Data represent mean ± SD of all mice per group (n = 10)Back to article page